| ²é¿´: 1189 | »Ø¸´: 1 | |||
springsunyjÖÁ×ðľ³æ (ÎÄѧ̩¶·)
|
[½»Á÷]
2012Äê¶ÈNSFCÓëÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº£¨NIH£©ÉúÎïҽѧºÏ×÷ÏîĿָÄÏ ÒÑÓÐ1È˲ÎÓë
|
|
2012Äê¶È¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίԱ»á£¨NSFC£©ÓëÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº£¨NIH£©ÉúÎïҽѧºÏ×÷ÏîĿָÄÏ -------------------------------------------------------------------------------- ×÷Õß:ÁõÐãÆ¼¡¡¡¡¡¡·¢±íʱ¼ä:2011-12-21¡¡¡¡¡¡Õª×Ô:¹ú¼ÊºÏ×÷¾Ö ¡¡¡¡¸ù¾Ý¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίԱ»á£¨NSFC£©ÓëÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿Ôº£¨NIH£©2010ÄêÇ©ÊðµÄ¿ÆÑ§ºÏ×÷Á½ⱸÍü¼ºÍ2010Äê12ÔÂÇ©ÊðµÄʵʩϸÔò£¬Ë«·½¹²Í¬×ÊÖúÒ»ÄêÆÚºÏ×÷ÏîÄ¿£¬Ö§³ÖÖÐÃÀ¿ÆÑ§¼ÒÔÚÖ×Áö¡¢¾«Éñ½¡¿µ¡¢¹ýÃôÐÔ¼²²¡¡¢¸ÐȾÐÔ¼²²¡£¨°üÀ¨HIV/°¬×̲¡¼°Æä²¢·¢Ö¢£©ºÍҽѧÃâÒßµÈÁìÓò¿ªÕ¹ºÏ×÷¡£¾ßÌåÏîĿ˵Ã÷ºÍÉêÇëÒªÇóÈçÏ£º ¡¡¡¡Ò»¡¢ ÏîĿ˵Ã÷ ¡¡¡¡£¨Ò»£©×ÊÖúÏîÄ¿Êý£º48Ïî×óÓÒ ¡¡¡¡£¨¶þ£©×ÊÖúÄÚÈÝÓëÇ¿¶È£º ¡¡¡¡NSFCÓëNIH·Ö±ð¸ºÔð×ÊÖú±¾¹ú¿ÆÑ§¼ÒµÄÑо¿¾·Ñ¡¢Îª¿ªÕ¹Ë«±ß½»Á÷ËùÐèµÄ³ö·Ã¹ú¼ÊÂ÷Ѽ°¹úÍâÉú»î·Ñ¡£NSFC¶Ôÿ¸öÏîĿƽ¾ù×ÊÖú30ÍòÔª£¬NIH¶Ôÿ¸öÏîÄ¿×ÊÖúԼΪ5ÍòÃÀÔª»ò10ÍòÃÀÔª¡£ ¡¡¡¡×¢Ò⣺NIH¸ù¾ÝÃÀ·½ÉêÇëÈ˵ÄÉí·Ý£¬·ÖΪԺÍ⣨extramural£©»òÔºÄÚ£¨intramural£©Á½¸öÏîÄ¿ÉêÇëÖ¸ÄÏ¡£ÔºÍâÉêÇëÖ¸ÄÏÕë¶ÔµÄÃÀ·½ÉêÇëÈËΪ·ÇNIHËùÊô¸÷Ñо¿ËùµÄÑо¿ÈËÔ±£»ÔºÄÚÉêÇëÖ¸ÄÏÕë¶ÔµÄÃÀ·½ÉêÇëÈËΪNIHËùÊô¸÷Ñо¿ËùµÄÄÚ²¿Ñо¿ÈËÔ±¡£±¾´ÎNIH¶ÔÔºÍâÏîÄ¿µÄ×ÊÖúÇ¿¶ÈԼΪ10ÍòÃÀÔª/Ï¶ÔÔºÄÚÏîÄ¿µÄ×ÊÖúÇ¿¶ÈԼΪ5ÍòÃÀÔª/Ïî¡£ ¡¡¡¡ÈçÐèÏêÇ飬¿É²ÎÔÄNIHÖ¸ÄÏÈçÏ£º1¡¢NIHÔºÍâÖ¸ÄÏÁ´½Ó£ºhttp://grants.nih.gov/grants/gui ... /NOT-CA-12-002.html£» 2¡¢NIHÒÑͨ¹ýEmail·½Ê½ÏòÆäÔºÄÚÈËÔ±¹«²¼ÁËÆäÔºÄÚÖ¸ÄÏ£¬¸ÃÖ¸ÄÏÄÚÈÝÇë²Î¼û±¾ÖÐÎÄÖ¸ÄÏÎÄÄ©Ëù¸½µÄÓ¢ÎÄÐÅÏ¢¡£ ¡¡¡¡£¨Èý£©ÏîĿִÐÐÆÚ£º2013Äê1ÔÂ1ÈÕ-2013Äê12ÔÂ31ÈÕ¡£ ¡¡¡¡£¨ËÄ£©×ÊÖúÁìÓò¼°ÉêÇë´úÂ룺 ¡¡¡¡ºóÃæÁгöµÄ×ÊÖúÁìÓòºÍ·½ÏòÖ»ÊǾÙÀý˵Ã÷£¬Ë«·½×ÊÖúµÄÁìÓò²¢²»½öÏÞÓÚ´Ë£¬Ö»ÒªÉêÇëÈ˵ÄÑо¿ÄÚÈÝÓëÖ×Áö¡¢¾«Éñ½¡¿µ¡¢ ¹ýÃôÐÔ¼²²¡¡¢¸ÐȾÐÔ¼²²¡£¨°üÀ¨HIV/°¬×̲¡¼°Æä²¢·¢Ö¢£©»òҽѧÃâÒßÏà¹Ø£¬¾ù¿É°´ÕÕ±¾ÏîĿָÄϵÄÒªÇóÌá½»ÉêÇë¡£ ¡¡¡¡Öз½ÉêÇëÈËÐëÑ¡ÔñÒÔÏÂÁгöµÄÉêÇë´úÂ루H16»òH09»òH10»òH19£©ÌîдÖÐÎÄÉêÇëÊ飬¶ÔÓÚδ°´ÒªÇóÌîд´ËÖ¸¶¨ÉêÇë´úÂëµÄÉêÇëÊ飬½«²»ÓèÊÜÀí¡£ ¡¡¡¡×¢£º1¡¢Ò©Îï¡¢ÉúÎïÖÆ¼ÁºÍÕï¶ÏѧµÄÁÙ´²ÊÔÑé²»ÊôÓÚ±¾Ö¸ÄÏ×ÊÖú·¶Î§¡£ ¡¡¡¡¡¡¡¡2¡¢¹ÄÀøÎ§ÈÆ¿ÆÑ§ÎÊÌ⿪չµÄºÏ×÷Ñо¿£¬±ÜÃâÒÔÑùÆ·½»»»ÎªÖ÷ÒªÄÚÈݵĺÏ×÷¡£Èç±ØÐëÉæ¼°ÑùÆ·½»»»ÎÊÌ⣬Öз½ÉêÇëÈËÐë»ñµÃ¹ú¼ÒÏàÓ¦²¿ÃÅÅú×¼£¬É걨ʱÐ븽ÉÏÓйØÊéÃæÅú×¼²ÄÁÏ¡£ ¡¡¡¡¡¡¡¡3¡¢¶ÔÉæ¼°Ò½Ñ§Â×ÀíµÄÑо¿ÏîÄ¿,ÇëÌṩËùÔÚµ¥Î»»òÉϼ¶Ö÷¹Üµ¥Î»Â×ÀíÉó²éίԱ»áµÄÅú×¼Êé¡£ ¡¡¡¡1¡¢Ö×ÁöÁìÓò¡¾ÉêÇë´úÂ룺H16¡¿ ¡¡¡¡¡ñ ¶ÔÖÐÃÀÁ½¹ú³£¼ûÖ×ÁöµÄ²¡ÀíѧÑо¿£¨Studies on the pathobiology of cancers in China or the U.S.£© ¡¡¡¡¡ñ ¶Ôº±¼ûÖ×ÁöµÄºÏ×÷Ñо¿£¨Studies of rare tumors where there is a benefit to U.S.-China cooperation to identify sufficient numbers of cases for study£© ¡¡¡¡¡ñ Óë¸ÐȾÏà¹ØµÄÖ×Áö£¨Infection-associated cancers£© ¡¡¡¡¡ñ »ù´¡Ö×ÁöÑо¿£¨Basic cancer research£© ¡¡¡¡¡¡1£©Ö×Áö»ùÒò×éѧ£¬°üÀ¨±í¹Û»ùÒò×éѧ¡¢×ªÂ¼×éѧ¡¢µ°°×ÖÊ×éѧºÍ´úл×éѧÑо¿£¨Cancer genomics, including epigenomic, transcriptomic, proteomic and metabolomic studies£© ¡¡¡¡¡¡2£©ÏµÍ³ÉúÎïѧºÍ½á¹¹ÉúÎïѧ£¨Systems biology and structural biology£© ¡¡¡¡¡¡3£©Ö×ÁöÄÉÃ×¼¼Êõ£¨Cancer nanotechnology£© ¡¡¡¡¡¡4£©Ö×Áöϸ°ûºÍÖ×ÁöÉúÎïѧ£¨Cancer cell and tumor biology£© ¡¡¡¡¡¡5£©Ö×Áö¸Éϸ°û£¨Cancer stem cells£© ¡¡¡¡¡¡6£©Î¢»·¾³ºÍÖ×Áö×ªÒÆ¡¢Ö×ÁöÃâÒߺÍÃâÒßÖÎÁÆ¡¢Ö×Áö²¡Òòѧ£¨Microenvironment and metastasis, tumor immunology and immunotherapy, and cancer etiology£© ¡¡¡¡¡¡7£©Ö×ÁöºÍÑ×Ö¢£¨Cancer and inflammation£© ¡¡¡¡¡ñ Ö×ÁöÁ÷Ðв¡ºÍÈËȺÑо¿£¬°üÀ¨´«È¾Ô´¡¢ÓªÑø¡¢»·¾³ºÍÖ°Òµ±©Â¶¶ÔÓÕ·¢Ö×ÁöµÄÓ°Ï죨Cancer epidemiology and population science studies, including investigations of infectious agents, nutrition, energy balance, environmental and occupational exposures or personal susceptibility factors that may affect cancer risk£© ¡¡¡¡¡ñ Ö×ÁöµÄÔ¤·ÀºÍɸ²éÑо¿£¬°üÀ¨µÍ³É±¾É¸²é¡¢»¯Ñ§Ô¤·À¡¢Ö×ÁöÓëÓªÑø¡¢Ö×ÁöµÄÔçÆÚ·¢ÏÖ£¨Cancer prevention and screening studies, including: cost-effective screening; chemoprevention; nutrition; early detection£© ¡¡¡¡¡ñ Ö×ÁöÐÂÁÆ·¨ºÍÏÔÏñ¼ÁµÄ»ù´¡Ñо¿£¨Preclinical development of novel cancer therapeutics and imaging agents£© ¡¡¡¡¡ñ ͨ¹ýÖÐÒ½Ñо¿£¬1) ´ÓÊÀ½çÎÀÉú×éÖ¯¹æ¶¨µÄ(http://www.who.int/medicines/are ... ions/en/index.html)´«Í³Ò½ÁÆÌåϵҩµäÖз¢¾òÐÂÁÆ·¨£¨identify novel therapeutics in the pharmacopeia of traditional medical systems as defined by the World Health Organization£©£»2) ʹÓû¥²¹µÄ·½·¨Ìá¸ßÏÖÓеıê×¼ÐͺÍÑо¿ÐÍ¿¹°©ÁÆ·¨µÄÖÎÁƱÈÀý£¨Use of complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies£©£»ÒÔ¼°3) Ñо¿Éú»î·½Ê½µÄ¸Ä±ä¶ÔÖ×ÁöÔ¤ºóµÄÓ°Ï죨 research on lifestyle modifications£¨e.g. diet, exercise, mind-body approaches£©and their effect on cancer outcome(e.g. response to conventional cancer therapy, survival)£© ¡¡¡¡2¡¢¾«Éñ½¡¿µÁìÓò¡¾ÉêÇë´úÂ룺H09 ¡¿ ¡¡¡¡¡ñ Ñо¿Ó뾫Éñ¼²²¡ÃÜÇÐÏà¹ØµÄÉñ¾»·Â·µÄ·¢Óý¡¢½á¹¹ºÍ¹¦ÄÜ¡£¿É°üÀ¨¶Ô·ÇÈËÁ鳤ÀàµÄ½âÆÊºÍ³ÉÏñÑо¿£¨Analyses of the development, structure, and function of neural circuits with a focus on those most relevant to mental disorders. These studies could include anatomic and imaging projects in non-human primates.£©£» ¡¡¡¡¡ñ ·¢Õ¹ÐµÄÑо¿¼¼ÊõºÍ·½·¨£¬°üÀ¨£º³ÉÏñ¹¤¾ß¡¢»ùÓÚϸ°ûÄ£Ð͵ĸßͨÁ¿±íÐͼì²â¡¢ÒÔ¼°ÓÃÓÚÑо¿¾«Éñ¼²²¡·Ö×ÓºÍϸ°û»úÀíµÄ¸Éϸ°û¼¼ÊõµÄ¸Ä½ø£¨Development of novel tools and methodologies, including imaging tools, assays that allow high throughput phenotyping within cell models, and improvements in stem cell techniques to study the molecular and cellular basis of mental disorders£©£» ¡¡¡¡¡ñ ÁÙ´²Ç°¿ª·¢Ðµľ«Éñ¼²²¡µÄÖÎÁÆ·½·¨£¨Preclinical development of novel therapeutics for mental disorders£©£» ¡¡¡¡¡ñ ѰÕÒ¾ßÓÐÕï¶ÏºÍÖÎÁÆÔ¤²â¼ÛÖµµÄÉúÎï±ê¼ÇÎIdentification of biomarkers with predictive value for diagnosis and treatment£©£» ¡¡¡¡¡ñ ¾«Éñ·ÖÁѵÄǰÆÚÖ¢×´Ñо¿£¨Studies of the prodrome of schizophrenia£©¡£ ¡¡¡¡3¡¢HIV/°¬×̲¡ÁìÓò¡¾ÉêÇë´úÂ룺H19¡¿ ¡¡¡¡¡ñ HIV¸ÐȾºÍ°¬×̲¡¼°Æä²¢·¢Ö¢ºÍ¹²»¼¼²²¡£¨°üÀ¨ºÏ²¢¸ÐȾ¡¢¶ñÐÔÖ×Áö¡¢¿¹Äæ×ªÂ¼²¡¶¾ÖÎÁƺϲ¢Ö¢¡¢½áºË¡¢¸ÎÑס¢´úлÒì³£¡¢ÐÄѪ¹Ü¡¢ÀÏÄêÉñ¾ÈÏÖª¹¦ÄÜÕϰ£©£¨HIV/AIDS and its co-morbidities including , but not limited to, co-infections, AIDS-defining and non-AIDS defining malignancies, and complications associated with long-term HIV disease and antiretroviral therapy (ART), including tuberculosis, hepatitis C and hepatitis B, metabolic disorders, cardiovascular disease, conditions associated with aging, and neurologic and neurocognitive disorders.£© ¡¡¡¡¡ñ HIV/°¬×̲¡ÖÎÁƵÄÑо¿£ºHIV²¡¶¾¿â¡¢Ç±·üÆÚºÍ¸ÐȾ³ÖÎÈ£»É¸²é¼°²âÊÔÐµĻ¯ºÏÎ´Ó²¡¶¾Ñ§¡¢ÃâÒßѧ¡¢Ï¸°ûÖÎÁÆÑ§¼°Ç±·ü²¡¶¾¼¤»î²ßÂԽǶÈÑо¿ÐµÄÖÎÁÆ·½·¨£»ÒÔ¼°ÔÚ¸öÌå¡¢ÉçÇøºÍÈËȺ²ã´ÎµÄHIV/°¬×̲¡ÁÆ·¨µÄÑо¿¡££¨Research toward a cure for HIV/AIDS including studies on: HIV reservoirs, latency and persistence; screening and testing of novel compounds; developing and testing novel approaches combining virologic-, immunologic-, and cellular-based therapies, as well as strategies to activate latent virus; and adherence to treatment regimens, as well as research at the individual, community, and population levels on developing and implementing a cure for HIV/AIDS.£© ¡¡¡¡4¡¢¹ýÃôÐÔ¼²²¡¡¾ÉêÇë´úÂ룺H10¡¿¡¢Ò½Ñ§ÃâÒßѧ¡¾ÉêÇë´úÂ룺H10¡¿ºÍ¸ÐȾÐÔ¼²²¡¡¾ÉêÇë´úÂ룺H19¡¿ ¡¡¡¡¡ñ Ïø´ºÍ¹ýÃôÐÔ¼²²¡£¬°üÀ¨»·¾³ÎÛȾÎï¡¢¸ÐȾ¼°¹ýÃôÔµÄÓ°Ï죨Asthma and allergic disease, including the role of environmental pollutants, infections and allergens£© ¡¡¡¡¡ñ ҽѧÃâÒßѧ£¨Basic immunology and immunity studies£© ¡¡¡¡¡ñ ¶ÔÒÔÏ·ÇHIV/AIDS´«È¾²¡µÄÑо¿£º ¡¡¡¡Å±¼²¡¢·Î½áºË¡¢µÇ¸ïÈÈ¡¢³¦²¡¶¾71ÐÍ¡¢¿ñÈ®²¡¡¢ÑªÎü³æ²¡¡¢ÂéÕ¸ÎÑ×£¬»òÁ÷¸Ð£¬ÒÔÉÏÑо¿Ó¦Éæ¼°ÈçÏÂÁìÓòÖ®Ò»£º£¨1£©ÄÍÒ©ÐÔ¼°ÆäÄÍÒ©»úÖÆÑо¿£»£¨2£©¼²²¡Ã½½éÉúÎïµÄÄÍÒ©ÐÔ£»£¨3£©¶Ô´«È¾²¡ºÍÒßÃçµÄÃâÒß·´Ó¦£¬º¬ÃâÒß·´Ó¦ÔÚ·¢²¡»úÀí·½ÃæÆðµÄ×÷Óã¨Research on infectious diseases (non-HIV/AIDS) should focus on malaria, tuberculosis, dengue fever, enterovirus 71, rabies, schistosomiasis, measles, hepatitis£¬or influenza, and include one of the following areas: ¡¡¡¡¡ñ Antimicrobial resistance, including mechanisms of resistance ¡¡¡¡¡ñ Resistance in disease vectors ¡¡¡¡¡ñ Immune responses to infectious diseases or vaccines, including the role of immune responses in pathogenesis£© ¡¡¡¡¶þ¡¢ÉêÇëÒªÇó ¡¡¡¡£¨Ò»£©Öз½ÉêÇëÈËÐë¾ßÓи߼¶×¨Òµ¼¼ÊõÖ°Îñ£¨Ö°³Æ£©£¬ÐëÊÇÕýÔڳе£»ò³Ðµ£¹ý3ÄêÆÚÒÔÉϹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÏîÄ¿µÄ¸ºÔðÈË£» ¡¡¡¡£¨¶þ£©ÖÐÃÀË«·½¿ÆÑ§¼ÒÖ®¼äÓ¦ÓнϺõĺÏ×÷»ù´¡ºÍDZÁ¦£» ¡¡¡¡£¨Èý£©NIHµÄ×ÊÖú¶ÔÏó°üÀ¨ÆäÔºÍ⣨extramural£©Ñо¿ÈËÔ±£¨Ö¸·ÇNIHËùÊô¸÷Ñо¿ËùµÄÑо¿ÈËÔ±£©ºÍÔºÄÚ£¨intramural£©Ñо¿ÈËÔ±£¨Ö¸NIHËùÊô¸÷Ñо¿ËùÄÚ²¿Ñо¿ÈËÔ±£©¡£NIH¶ÔÔºÍâºÍÔºÄÚÈËÔ±µÄÉêÇëÓв»Í¬µÄÒªÇó£¬ÃÀ·½ºÏ×÷ÕßÐë°´ÕÕNIH·Ö±ð·¢²¼µÄÏîÄ¿Õ÷¼¯Ö¸ÄÏ£¨1¡¢NIHÔºÍâÖ¸ÄÏÁ´½Ó£ºhttp://grants.nih.gov/grants/gui ... /NOT-CA-12-002.html£» 2¡¢NIHÒÑͨ¹ýEmail·½Ê½ÏòÆäÔºÄÚÈËÔ±¹«²¼ÁËÆäÔºÄÚÖ¸ÄÏ£¬¸ÃÖ¸ÄÏÄÚÈÝÇë²Î¼û±¾ÖÐÎÄÖ¸ÄÏÎÄÄ©Ëù¸½µÄÓ¢ÎÄÐÅÏ¢£©ÖеľßÌåÒªÇó½øÐÐÉ걨¡£Öз½ÉêÇëÈ˺ÍÃÀ·½ºÏ×÷ÕßÒª³ä·Ö¹µÍ¨ÐÉÌ£¬ÔÚ´Ë»ù´¡ÉÏÌîдNIHÒªÇóµÄÓ¢ÎÄÉêÇë²ÄÁÏ¡£¸ÃÓ¢ÎÄÉêÇë²ÄÁÏÓÉÃÀ·½ºÏ×÷ÕßÌîд£¬Öз½ÉêÇëÈËÓ¦ÓëÃÀ·½ºÏ×÷ÕßÁªÏµ£¬È¡µÃÆäÏòNIH×îÖÕÌá½»µÄÈ«Ì×ÉêÇë²ÄÁϵĸ±±¾£¬×÷ΪÖз½ÉêÇëÈËÏòNSFCÌá½»ÉêÇëµÄ±ØÒª¸½¼þ²ÄÁÏ¡£¸ÃÓ¢ÎÄÉêÇë²ÄÁϽ«×÷Ϊ˫·½ÆÀÉóµÄÒÀ¾Ý£¬ÖÐÃÀË«·½×ÊÖú»ú¹¹¼°Ë«·½¿ÆÑ§¼ÒÐëÑϸñ×ñÊØË«·½Ïà¹Ø±£Ãܹ涨¡£ ¡¡¡¡ÎÞ´ËÓ¢ÎIJÄÁϸ½¼þµÄÖз½ÉêÇëÊÓΪÎÞЧ¡£ ¡¡¡¡£¨ËÄ£©Ë«·½ºÏ×÷ÕßÓ¦°´ÕÕÒªÇó·Ö±ðÏòÎÒίºÍNIHÌá½»ÉêÇ룬µ¥·½ÉêÇëÊÓΪÎÞЧ¡£ ¡¡¡¡×¢Ò⣺NIH¶ÔÓÚÆäÔºÄÚÉêÇëÈËÔ±£¬ÒªÇóÓÚ2012Äê1ÔÂ13ÈÕ֮ǰÏòNIHÌá½»ÒâÏòÊ飨Letter of Interest£©£¬Öз½ÉêÇëÈ˲»ÐèÒªÏòÎÒίÌá½»´ËÒâÏòÊ飬µ«ÊǶÔÓÚ½«ÓëNIHÔºÄÚÈËÔ±¿ªÕ¹ºÏ×÷µÄÖз½ÉêÇëÈË£¬Ó¦»ý¼«ÅäºÏÆäÃÀ·½ºÏ×÷ÕßÔÚ2012Äê1ÔÂ13ÈÕǰÏòNIHÌá½»ÒâÏòÊé¡£NIH¶ÔÓÚÆäÔºÍâÉêÇëÈËÔ±£¬²»ÒªÇóÌá½»ÒâÏòÊ飨Letter of Interest£©¡£ ¡¡¡¡Èý¡¢ÏÞÏî¹æ¶¨ ¡¡¡¡£¨Ò»£©´ËÏîĿΪһÄêÆÚºÏ×÷ÏîÄ¿£¬Öз½ÉêÇëÈ˲»²ÎÓë»ù½ðίµÄÏîÄ¿ÏÞÏî²éÖØ¡£ ¡¡¡¡£¨¶þ£©Öз½ÉêÇëÈË£¨²»º¬²ÎÓëÕߣ©Í¬ÄêÖ»ÄÜÉêÇë1Ïî±¾ÏîÄ¿¡£ÃÀ·½ÉêÇëÈËÓ¦×ñÑNIHµÄÏà¹ØÏÞÏî¹æ¶¨¡£ ¡¡¡¡ËÄ¡¢É걨˵Ã÷ ¡¡¡¡£¨Ò»£©Öз½ÉêÇëÈËÐëµÇ¼ISIS¿ÆÑ§»ù½ðÍøÂçϵͳ£¨http://isis.nsfc.gov.cn£©£¬ÔÚÏßÌ¡¶¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¹ú¼Ê£¨µØÇø£©ºÏ×÷Óë½»Á÷ÏîÄ¿ÉêÇëÊé¡·(ÒÔϼò³Æ¡°ÖÐÎÄÉêÇëÊ顱)¡£¾ßÌå²½ÖèÊÇ£º ¡¡¡¡1¡¢Öз½ÉêÇëÈËʹÓÃ×Ô¼ºµÄÓû§ÃûºÍÃÜÂëµÇ¼×ÔÈ»¿ÆÑ§»ù½ðίÏîÄ¿É걨ϵͳhttp://isis.nsfc.gov.cn ºóµã»÷¡°ÏîÄ¿ÉêÇ롱½øÈëÉêÇë½çÃæ£» ¡¡¡¡2¡¢µã»÷¡°ÐÂÔöÏîÄ¿ÉêÇ롱£¬½øÈëÏîÄ¿Àà±ðÑ¡Ôñ½çÃæ£¬µã»÷¡°¹ú¼Ê(µØÇø)ºÏ×÷Óë½»Á÷ÏîÄ¿¡±×ó²àÊÇ¡°+¡±ºÅ»òÕßÓҲࡰչ¿ª¡±Å¥£» ¡¡¡¡3¡¢Õ¹¿ª´ËÀàÏîÄ¿ÏÂÀ²Ëµ¥£¬ÔÙµã»÷¡°ºÏ×÷Ñо¿£¨×éÖ¯¼äÐÒéÏîÄ¿£©¡±ÓÒ²àµÄ¡°ÌîдÉêÇ롱£¬½øÈëÑ¡Ôñ¡°ºÏ×÷ÐÒ顱½çÃæ£¬ÇëÔÚÏÂÀ²Ëµ¥ÖÐÑ¡Ôñ¡°NSFC-NIHÏîÄ¿£¨ÖÐÃÀ£©¡±£¬Í¬Ê±ÊäÈëÒªÒÀÍеĻù½ðÏîÄ¿Åú×¼ºÅ¡£Í¨¹ý×ʸñÈÏÖ¤ºó¼´½øÈë¾ßÌåÉêÇëÊéÌîд½çÃæ¡£ ¡¡¡¡×¢Ò⣺ÉêÇëÊéÌîдÍê³Éºó£¬µã»÷¡°Ìá½»¡±°´Å¥È·ÈÏÌá½»³É¹¦ºó£¬ÔÙ´òÓ¡Ö½ÖÊÉêÇëÊé¡£ ¡¡¡¡£¨¶þ£©ÖÐÎÄÉêÇëÊéµÄÄÚÈÝÓ¦ÓëÓ¢ÎÄÉêÇë²ÄÁÏÄÚÈÝÒ»Ö¡£Í¬Ê±£¬ÖÐÎÄÉêÇëÊéÌîдµÄ±¾ºÏ×÷ÏîĿӢÎÄÃû³Æ±ØÐëÓëÃÀ·½ºÏ×÷ÕßÌá½»µÄÉêÇë²ÄÁÏÖеÄÓ¢ÎÄÏîÄ¿Ãû³ÆÍêȫһÖ¡£ ¡¡¡¡£¨Èý£©ÉêÇ븽¼þ²ÄÁÏ£º ¡¡¡¡1¡¢Öз½ÉêÇëÈ˳ýÁËÔÚÏßÌîдÌá½»ÖÐÎÄÉêÇëÊéÒÔÍ⣬»¹ÐëͬʱÌá½»£¨ÔÚISISϵͳÄÚÒÔ¸½¼þÐÎʽÉÏ´«£¬Í¬Ê±»¹Ðë´òÓ¡Ö½Öʰ汨ËÍ£©ÃÀ·½ºÏ×÷ÕßÏòNIHÌá½»µÄÈ«Ì×Ó¢ÎÄÉêÇë²ÄÁϵĸ±±¾¡£ÎÞ´ËÈ«Ì×Ó¢ÎÄÉêÇë²ÄÁϸ±±¾µÄ£¬ÊÓΪÎÞЧÉêÇë¡£ÓÉÓÚÃÀ·½ÉêÇëÈË·ÖΪNIHÔºÍ⣨extramural£©»òÔºÄÚ£¨intramural£©ÈËÔ±£¬NIH¶ÔÈ«Ì×Ó¢ÎIJÄÁϵÄÒªÇóÓÐËù²»Í¬£¬·Ö±ð¼ûÏÂÁУº ¡¡¡¡¶ÔÓÚÃÀ·½ºÏ×÷ÕßÊÇNIHÔºÍâÈËÔ±µÄ£º ¡¡¡¡£¨1£©Cover Letter£¨·âÃæÐÅ£©¡£×¢Ò⣺´ËÐÅÖÐË«·½ÉêÇëÈ˵ÄÓ¢ÎÄÐÕÃûºÍµ¥Î»Ó¦ÓëÖз½ÉêÇëÈËÌá½»µÄÖÐÎÄÉêÇëÊéÉϵÄË«·½ÉêÇëÈËÓ¢ÎÄÐÕÃûºÍµ¥Î»±£³ÖÒ»Ö£¨Ë«·½µÄÓ¢ÎÄÐÕÃû˳ÐòΪ£ºÐÕ£¨È«²¿´óд×Öĸ£©Ãû£¨Ê××Öĸ´óд£¬ÆäÓàСд£©¡£ÀýÈ磺ÍõÒ»µÄÓ¢ÎÄÐÕÃûµÄ±íʾΪ£ºWANG Yi£©¡£ ¡¡¡¡£¨2£©PHS 398 Form Page 1£¨NIHµÄPHS 398±íµÚ1Ò³£© ¡¡¡¡£¨3£©PHS 398 Form Page 2£¨NIHµÄPHS 398±íµÚ2Ò³£© ¡¡¡¡£¨4£©A brief description of the project that is being proposed in collaboration with the Chinese co-investigator £¨ºÏ×÷Ñо¿ÏîÄ¿¼ò½é£© ¡¡¡¡£¨5£©Letter of Confirmation£¨È·ÈϺ¯£©¡£´ËÈ·ÈϺ¯ÓÉÖÐÃÀË«·½¹²Í¬Ç©Êð¡£×¢Ò⣺´ËÐÅÖÐË«·½ÉêÇëÈ˵ÄÓ¢ÎÄÐÕÃûºÍµ¥Î»Ó¦ÓëÖз½ÉêÇëÈËÌá½»µÄÖÐÎÄÉêÇëÊéÉϵÄË«·½ÉêÇëÈËÓ¢ÎÄÐÕÃûºÍµ¥Î»±£³ÖÒ»Ö£¨Ë«·½µÄÓ¢ÎÄÐÕÃû˳ÐòΪ£ºÐÕ£¨È«²¿´óд×Öĸ£©Ãû£¨Ê××Öĸ´óд£¬ÆäÓàСд£©¡£ÀýÈ磺ÍõÒ»µÄÓ¢ÎÄÐÕÃûµÄ±íʾΪ£ºWANG Yi£©¡£Öз½ÔÚÈ·ÈϺ¯ÉϵÄÇ©×ÖÈ˱ØÐëÊDZ¾ºÏ×÷ÏîÄ¿µÄÉêÇëÈ˱¾ÈË£¬ÏîÄ¿×é²ÎÓëÕß²»µÃÇ©×Ö¡£ ¡¡¡¡£¨6£©Biographical Sketches £¨ÃÀ·½ÈËÔ±¼òÀú£© ¡¡¡¡£¨7£©Budget£¨ÃÀ·½Ô¤Ë㣩 ¡¡¡¡£¨8£©Human Subjects/Vertebrate Animal Documentation£¨ÒÔÈË»ò¼¹×µ¶¯ÎïΪÑо¿¶ÔÏóʱӦ·ûºÏÖÐÃÀÁ½¹úÏà¹ØÕþ²ßµÄÖ¤Ã÷Îļþ£¬½öÊÊÓÃÓÚÉæ¼°ÒÔÈË»ò¼¹×µ¶¯ÎïΪÑо¿¶ÔÏóµÄÏàÓ¦ÏîÄ¿£© ¡¡¡¡£¨9£©PHS 398 Form £¨PHS 398Çåµ¥±í£© ¡¡¡¡£¨10£©Import of Biospecimens£¨ÉúÎïÑù±¾½ø¿ÚÅú×¼Ö¤Ã÷£¬½öÊÊÓÃÓÚÉæ¼°µ½ÉúÎïÑù±¾½ø¿ÚµÄÏàÓ¦ÏîÄ¿£© ¡¡¡¡¶ÔÓÚÃÀ·½ºÏ×÷ÕßÊÇNIHÔºÄÚÈËÔ±µÄ£¬ ¡¡¡¡£¨1£©Cover Letter£¨·âÃæÐÅ£©¡£×¢Ò⣺´ËÐÅÖÐË«·½ÉêÇëÈ˵ÄÓ¢ÎÄÐÕÃûºÍµ¥Î»Ó¦ÓëÖз½ÉêÇëÈËÌá½»µÄÖÐÎÄÉêÇëÊéÉϵÄË«·½ÉêÇëÈËÓ¢ÎÄÐÕÃûºÍµ¥Î»±£³ÖÒ»Ö£¨Ë«·½µÄÓ¢ÎÄÐÕÃû˳ÐòΪ£ºÐÕ£¨È«²¿´óд×Öĸ£©Ãû£¨Ê××Öĸ´óд£¬ÆäÓàСд£©¡£ÀýÈ磺ÍõÒ»µÄÓ¢ÎÄÐÕÃûµÄ±íʾΪ£ºWANG Yi£©¡£ ¡¡¡¡£¨2£©Abstract£¨ÏîĿժҪ£© ¡¡¡¡£¨3£©Research Plan£¨ºÏ×÷Ñо¿¼Æ»®£© ¡¡¡¡£¨4£©References£¨²Î¿¼ÎÄÏ×£© ¡¡¡¡£¨5£©Budget£¨ÃÀ·½Ô¤Ë㣩 ¡¡¡¡£¨6£©Letter of Confirmation£¨È·ÈϺ¯£©¡£´ËÈ·ÈϺ¯ÓÉÖÐÃÀË«·½¹²Í¬Ç©Êð¡£×¢Ò⣺´ËÐÅÖÐË«·½ÉêÇëÈ˵ÄÓ¢ÎÄÐÕÃûºÍµ¥Î»Ó¦ÓëÖз½ÉêÇëÈËÌá½»µÄÖÐÎÄÉêÇëÊéÉϵÄË«·½ÉêÇëÈËÓ¢ÎÄÐÕÃûºÍµ¥Î»±£³ÖÒ»Ö£¨Ë«·½µÄÓ¢ÎÄÐÕÃû˳ÐòΪ£ºÐÕ£¨È«²¿´óд×Öĸ£©Ãû£¨Ê××Öĸ´óд£¬ÆäÓàСд£©¡£ÀýÈ磺ÍõÒ»µÄÓ¢ÎÄÐÕÃûµÄ±íʾΪ£ºWANG Yi£©¡£Öз½ÔÚÈ·ÈϺ¯ÉϵÄÇ©×ÖÈ˱ØÐëÊDZ¾ºÏ×÷ÏîÄ¿µÄÉêÇëÈ˱¾ÈË£¬ÏîÄ¿×é²ÎÓëÕß²»µÃÇ©×Ö¡£ ¡¡¡¡£¨7£©Biographical Sketch £¨ÖÐÃÀË«·½PIµÄ¼òÀú£© ¡¡¡¡£¨8£©Roles of Key Staff£¨Ö÷Òª²Î¼ÓÈËÔ±µÄ·Ö¹¤£© ¡¡¡¡£¨9£©Human Subjects/Vertebrate Animal Documentation£¨ÒÔÈË»ò¼¹×µ¶¯ÎïΪÑо¿¶ÔÏóʱӦ·ûºÏÖÐÃÀÁ½¹úÏà¹ØÕþ²ßµÄÖ¤Ã÷Îļþ£¬½öÊÊÓÃÓÚÉæ¼°ÒÔÈË»ò¼¹×µ¶¯ÎïΪÑо¿¶ÔÏóµÄÏàÓ¦ÏîÄ¿£© ¡¡¡¡£¨10£©Import of Biospecimens£¨ÉúÎïÑù±¾½ø¿ÚÅú×¼Ö¤Ã÷£¬½öÊÊÓÃÓÚÉæ¼°µ½ÉúÎïÑù±¾³ö¿ÚµÄÏàÓ¦ÏîÄ¿£© ¡¡¡¡£¨11£©NIHÏà¹ØÑо¿Ëù»òÖÐÐÄ¿ÆÑ§Ö÷ÈΣ¨SD£©Í¬ÒâÉêÇë±¾ÏîÄ¿µÄµç×ÓÓʼþ»òÐź¯¡£ ¡¡¡¡½¨ÒéÖз½ÉêÇëÈËÔÚÉêÇë¹ý³ÌÖУ¬³ýÑϸñ×ñѱ¾Ö¸ÄÏÒªÇó£¬Í¬Ê±ÈÏÕæÔĶÁNIHµÄÏîÄ¿Õ÷¼¯Ö¸ÄÏ£¨1¡¢NIHÔºÍâÖ¸ÄÏÁ´½Ó£ºhttp://grants.nih.gov/grants/gui ... /NOT-CA-12-002.html£» 2¡¢NIHÒÑͨ¹ýEmail·½Ê½ÏòÆäÔºÄÚÈËÔ±¹«²¼ÁËÆäÔºÄÚÖ¸ÄÏ£¬¸ÃÖ¸ÄÏÄÚÈÝÇë²Î¼û±¾ÖÐÎÄÖ¸ÄÏÎÄÄ©Ëù¸½µÄÓ¢ÎÄÐÅÏ¢£©µÄÏà¹ØÒªÇó£¬ÒÔÈ«ÃæÁ˽âË«·½µÄÔðÈκÍÒåÎñ¡£ ¡¡¡¡2¡¢Öз½ÉêÇëÈËÐëÁíҳרÃÅ˵Ã÷Öз½Ô¤Ë㣬²¢ÒÔ¸½¼þµÄÐÎʽÔÚISISϵͳÖÐÉÏ´«¡£ ¡¡¡¡3¡¢Öз½ÉêÇëÈ˼°Ö÷Òª²ÎÓëÕß»¹ÐëÁíÒ³ÒÔ¸½¼þÐÎʽÌá½»Ó¢ÎÄѧÊõ¼òÀú¡¢½üÆÚ¹«¿ª·¢±íµÄ´ú±íÐÔÎÄÕÂĿ¼£¨5ƪ£©¡£ ¡¡¡¡£¨ËÄ£©ÖÐÎÄÉêÇëÊéÌîдÍê³ÉÈ·ÈÏÎÞÎóºó£¬µã»÷Ìá½»£¬²¢½«ÏµÍ³×Ô¶¯Éú³ÉµÄPDFÎļþ´òÓ¡Ò»·Ý¡£µç×Ó°æÉêÇëÊé²¢±¾²¿·ÖµÚ£¨Èý£©ÌõËùÁгöµÄËùÓÐÉêÇ븽¼þ²ÄÁÏÐë¾ÒÀÍе¥Î»È·ÈϺóÔÚISISϵͳÖÐÌá½»£»Ö½ÖÊÉêÇëÊé¾ÒÀÍе¥Î»Ç©×Ö¸ÇÕºó£¬Á¬Í¬±¾²¿·ÖµÚ£¨Èý£©ÌõËùÁÐËùÓÐÉêÇ븽¼þ²ÄÁϵĴòÓ¡°æÒ»Ê½Ò»·Ý£¬Ò»²¢±¨ËÍ»ù½ðί¹ú¼ÊºÏ×÷¾ÖÃÀ´ó´¦ (µØÖ·¼ûºó)¡£ ¡¡¡¡×¢£ºÖ½Öʰæ²ÄÁÏÓ¦Óëµç×Ó°æ²ÄÁÏÍêȫһÖ£¬ÈκÎÒ»°æ²ÄÁϲ»È«µÄ£¬ÊÓΪÎÞЧÉêÇë¡£ ¡¡¡¡Îå¡¢Öз½ÏîÄ¿ÉêÇë½ØÖ¹Ê±¼ä£º ¡¡¡¡µç×ÓÉêÇë²ÄÁÏ£º2012Äê2ÔÂ24ÈÕÏÂÎç4µã£¨½ØÖ¹Ê±¼äÒÔISISϵͳÄÚÌύʱ¼äΪ׼£©£» ¡¡¡¡Ö½ÖÊÉêÇë²ÄÁÏ£º2012Äê2ÔÂ24ÈÕ£¨ÒÔÓÊ´ÁÈÕÆÚΪ׼£©¡£ ¡¡¡¡ÃÀ·½ÏîÄ¿ÉêÇë½ØÖ¹Ê±¼äΪ2012Äê2ÔÂ21ÈÕ£¬Ë«·½ÉêÇëÈËӦȷ±£¸÷×ÔÔÚÏîÄ¿ÉêÇë½ØÖ¹ÈÕÆÚǰÌá½»ÉêÇë¡£ ¡¡¡¡Î´°´ÉÏÊöʱÏÞÒªÇóÌá½»µÄÉêÇ룬½«²»ÓèÊÜÀí¡£ ¡¡¡¡Áù¡¢ÁªÏµ·½Ê½ ¡¡¡¡µØ¡¡Ö·£º±±¾©Êк£µíÇøË«Çå·83ºÅ ¡¡¡¡¡¡¡¡¡¡¡¡¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðίԱ»á¹ú¼ÊºÏ×÷¾ÖÃÀ´ó¼°¶«Å·´¦ ¡¡¡¡ÓÊ¡¡±à£º100085 ¡¡¡¡ÁªÏµÈË£ºÁõÐãÆ¼ κÇÛ ¡¡¡¡µç¡¡»°£º010-62325377£»010-62325544 ¡¡¡¡´«¡¡Õ棺010-62327004 ¡¡¡¡µç¡¡ÓÊ£ºliuxp@nsfc.gov.cn£»weiqin@nsfc.gov.cn ¡¡¡¡¸½£ºNIHÕë¶ÔÆäÔºÄÚÈËÔ±µÄÉêÇëÖ¸ÄÏ Á´½ÓµØÖ·£ºhttp://www.nsfc.gov.cn/Portal0/InfoModule_396/36203.htm |
» ²ÂÄãϲ»¶
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ4È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
zjf710
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 32 (СѧÉú)
- ½ð±Ò: 2352.2
- É¢½ð: 10
- ºì»¨: 7
- Ìû×Ó: 1521
- ÔÚÏß: 246Сʱ
- ³æºÅ: 2787502
- ×¢²á: 2013-11-08
- ÐÔ±ð: GG
- רҵ: ÖÐҽҩѧÑо¿Ð¼¼ÊõºÍз½

2Â¥2014-02-14 17:09:11














»Ø¸´´ËÂ¥

